Clinical Science Letters

622

Facial Dystrophic Calcinosis Cutis Secondary to Acne

T. Saavedra, F. Mardones, I. Sazunic, and X. Wortsman
Departamento de Dermatología, Hospital Clínico, Universidad de Chile, Santiago, Chile

To the Editor:

Acne is a common condition in the general population, mainly affecting older children and adolescents. Physical sequelae such as scarring and pigmentation disorders are often observed. However, other secondary lesions such as cutaneous calcification are occasionally reported in the literature.1 Calcinosis cutis occurs due to the deposition of calcium and phosphate salts in the skin and, in general, can develop around localized tissue damage or in association with systemic metabolic disorders. It is classified into 4 groups according to its etiology: dystrophic, metastatic, iatrogenic, and idiopathic; in some cases different mechanisms can coexist.2

We present 2 cases of dystrophic calcinosis cutis of the face as a sequela of inflammatory acne.

The patients were women of 48 and 58 years of age, with no past history of note. Both patients reported that they had had severe inflammatory acne during adolescence, mainly affecting the face, making particular mention of the repetitive traumatic manipulation of the facial lesions. They attended our department for treatment of the residual scars on their faces.

References

The women presented numerous depressed pinpoint scars and multiple, hard, asymptomatic, skin-colored papules of 2 to 3 mm in diameter (Figures 1 and 2). There were no other significant clinical findings.

Ultrasound was performed of the soft tissues of the papules, showing, in both cases, numerous hyperechogenic foci of calcified appearance, located in the dermis.

Histopathological study of the lesions revealed the presence of calcified nodules in the dermis associated with signs of actinic damage (Figure 3).

Laboratory studies showed no abnormalities of the plasma levels of calcium, phosphate, parathyroid hormone, or the markers of renal function, and the study for connective tissue diseases (antinuclear antibodies, extractable nuclear antigen, scleroderma-70) was negative.

Finally, the diagnosis of facial dystrophic calcinosis cutis secondary to acne was made.

In view of the number, spread, and site of the lesions, it was decided to start medical treatment with diltiazem at a dose of 60 mg a day for a period of 2 months. At the end of this period there was no clinical improvement and, furthermore, the patients reported poor tolerance of the medication; the therapy was therefore withdrawn. In the end, abrasive treatment was prescribed to ameliorate the facial scars.

The deposits of amorphous and insoluble calcium salts in the skin are formed mainly of amorphous calcium hydroxyapatite or phosphate crystals. There appear to be multiple local and systemic mechanisms that lead to the onset of this condition.

In the absence of a tissue lesion, ectopic deposits of calcium salts develop when the calcium phosphate product in plasma exceeds 70 mg/dL. If tissue damage is present, it has been suggested that the following pathogenic phenomena may play a role: increased intracellular calcium concentration, denaturation of proteins that preferentially bind phosphate, genetic mutations of elastic fibers and collagen, and increased γ-carboxyglutamic acid.

The majority of cases of calcinosis cutis are associated with connective tissue diseases. Dystrophic calcinosis cutis is the most common form and develops around localized tissue damage, with no alterations of calcium or phosphate metabolism. In general the patients have a past history of an underlying disease, previous injury, or inflammatory dermatosis.

The majority of cases of calcinosis cutis have a gradual onset and are asymptomatic; however, the history and clinical course of the condition vary mainly according to...
the etiology of the calcification. Clinical manifestations will also depend on the underlying disorder (if present), but usually there are multiple, hard, whitish papules, plaques, or nodules with a symmetrical distribution.

Morbidity depends on the extent and site of the cutaneous calcification; joints, muscles, and organs such as the lungs, kidneys, and intestine may also be affected. In addition, vascular deposits of calcium can give rise to distal ischemia and necrosis. Areas of ulceration or the transcutaneous elimination of a whitish-yellow, chalk-like material may be observed, and secondary infection can develop. The therapeutic measures used depend on the underlying disease; in general the outcomes are not very satisfactory and only the results of case reports are available.

Most medical treatments for calcinosis cutis have been described in patients with connective tissue diseases. They include warfarin, colchicine, probenecid, bisphosphonates, minocycline, and diltiazem. Success has also been reported with other treatment modalities, such as carbon dioxide laser and intralesional corticosteroid injection. Finally, surgery is a possible option to remove calcium deposits in necrotic or infected tissues.

In conclusion, calcinosis cutis is a rarely reported sequela of acne and represents a therapeutic challenge. Clinical suspicion and appropriate additional tests are required to reach the diagnosis.

Conflicts of Interest
The authors declare no conflicts of interest.

References

Melanoma and Retinoblastoma*

S. Martínez-García, L. Martínez-Pilar, E. Gómez-Moyano, and V. Crespo
Servicio de Dermatología y Venereología, Complejo Hospitalario Universitario Carlos Haya, Malaga, Spain

To the Editor:
Retinoblastoma is an embryonal tumor derived from retina cells that affects 5 in every 100 000 newborns and accounts for 3% of cancers in those children aged less than 15 years. It is the most common type of malignant intraocular tumor in children and the second most common for all age groups after melanoma.1

Most cases are diagnosed in the first 4 years of life. Presentation is unilateral in 60% to 75% of cases, and 60% are classed as sporadic.2 The remaining cases are bilateral and mostly hereditary.

Bilateral forms are caused by a double mutation in the Rb gene on the long arm of chromosome 13.3,4 The